Unproved Modality in the Treatment of Alzheimer‐Type Dementia
- 1 August 1985
- journal article
- case report
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 33 (8) , 548-551
- https://doi.org/10.1111/j.1532-5415.1985.tb04620.x
Abstract
Despite a dramatic increase in the understanding of the neuropathologic and neurochemical alterations accompanying Alzheimer's disease, by far the largest cause of progressive and incapacitating cognitive dysfunction in the elderly, physicians have as yet no pharmacologic agent that can be prescribed safely either to arrest or reverse this decline. This lack of effective therapeutic agents is contributing to the use by an increasing number of health professionals, including physicians and concerned families, of unproved, costly, and potentially dangerous modalities, such as chelation therapy. The purpose of this paper is to describe some individuals with Alzheimer-type dementia who have undergone chelation therapy. J Am Geriatr Soc 33:548, 1985Keywords
This publication has 8 references indexed in Scilit:
- Adverse Effects of Chelation TherapyPublished by American Medical Association (AMA) ,1983
- Senile dementia of the Alzheimer typeAnnals of Neurology, 1983
- Chelation Therapy in AtherosclerosisAnnals of Internal Medicine, 1982
- The Dialysis Dementia Syndrome and Aluminum IntoxicationNephron, 1982
- A FATAL ENCEPHALOPATHY IN CHRONIC HÆMODIALYSIS PATIENTSThe Lancet, 1976
- Brain Aluminum Distribution in Alzheimer's Disease and Experimental Neurofibrillary DegenerationScience, 1973
- EXPERIMENTAL PRODUCTION OF NEUROFIBRILLARY DEGENERATIONJournal of Neuropathology and Experimental Neurology, 1965